Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 (NYSE:PLX)

Earnings Call InsightsProtalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115Mar. 18, 2026 10:13 AM ETProtalix BioTherapeutics, Inc. (PLX) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Protalix BioTherapeutics (PLX) Q4 2025 Management View Dror Bashan, President and CEO, announced that the European Commission approved the 2 milligram per kilogram every 4-week dosing regimen for Elfabrio for adults with Fabry disease who are stable on enzymeNewsletters for Ever ...